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Ductal carcinoma in situ (DCIS) of the breast represents a group of heterogeneous non-
invasive lesions the incidence of which has risen dramatically since the advent of 
mammography screening. In this review we summarise current treatment trends and up-to-
date results from clinical trials studying surgery and adjuvant therapy alternatives, including 
the recent consensus on excision margin width and its role in decision-making for post-
excision radiotherapy. The main challenge in the clinical management of DCIS continues to 
be the tailoring of treatment to individual risk, in order to avoid the over-treatment of low-
risk lesions or under-treatment of DCIS with higher risk of recurring or progressing into 
invasion. While studies estimate that only about 40% of DCIS would become invasive if 
untreated, heterogeneity and complex natural history have prevented adequate 
identification of these higher-risk lesions. Here we discuss attempts to develop prognostic 
tools for the risk stratification of DCIS lesions and their limitations. Early results of a UK-wide 
audit of DCIS management (the Sloane Project) have also demonstrated a lack of 
consistency in treatment. In this review we offer up-to-date perspectives on current 
treatment and prediction of DCIS, highlighting the pressing clinical need for better 
prognostic indices. Tools integrating both clinical and histopathological factors together 
with molecular biomarkers may hold potential for adequate stratification of DCIS according 
to risk. This could help develop standardised practices of optimal management of patients 
with DCIS, improving clinical outcomes while providing only the amount of therapy required 
for each individual patient. 
Keywords (6): DCIS; ductal carcinoma in situ; breast cancer; risk prediction; prognostic tools; 
patient stratification. 
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1. INTRODUCTION  
The term ductal carcinoma in situ (DCIS) of the breast refers to precursor, non-invasive 
lesions comprising malignant epithelial cells which remain confined within the basal 
membrane of terminal duct lobular units of the breast[1,2]. DCIS encompasses a wide 
spectrum of lesions heterogeneous in grade, morphology, genomic profile and clinical 
presentation and represents almost 90% of all precursor (stage 0) breast cancers 
detected[3]. 
Before 1980, DCIS was considered relatively rare, accounting for less than 5% of breast 
cancer diagnoses[4], as most non-invasive lesions are typically non-palpable and 
asymptomatic and were often identified only after surgical resection of a suspicious breast 
mass[5,6]. In the last few decades, the advent of breast cancer mammography screening 
has resulted in a dramatic rise in DCIS detection. In the UK, incidence has increased by 534% 
since the 1970s and DCIS currently accounts for 20% of all screen-detected breast 
cancers[7]. 
Despite the limited knowledge of its natural history, DCIS has long been considered a 
precursor of invasive breast cancer (IBC)[2,8]. In the 1980s, Page and Dupont identified a 
series of women with untreated DCIS in breast biopsy samples and showed they had an 
increased risk of developing IBC[9]. Genetic similarities also support the precursor role of 
DCIS[10]. While the proportion of DCIS which develop into IBC if untreated remains 
uncertain, studies suggest this to be around 40%[11–13]. 
2. CURRENT THERAPEUTIC TRENDS 
2.1. Surgery 
DCIS is most frequently (>90%) detected during mammographic screening as 
indeterminate calcifications or microcalcifications[7]. Subsequently, a core biopsy is 
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performed for histological assessment and grading. DCIS is categorised into low, 
intermediate and high grades according to cellular and nuclear morphology and presence of 
mitoses (see Figure 1).  
In the UK, most patients (72%) diagnosed with DCIS on core biopsy undergo breast 
conserving surgery (BCS). Mastectomy may be performed depending on factors such as DCIS 
extent relative to breast size, type of DCIS, age and patient choice, as well as concern for risk 
of recurrence[14]. The increasing sensitivity of imaging techniques has resulted in more 
patients being diagnosed with extensive or multicentric disease, which presents challenges 
for surgical management. 
Traditionally, sentinel lymph node biopsy was performed for patients undergoing 
mastectomy for DCIS and for those with microinvasive disease, although this approach has 
been contested[15]. A recent study concluded that sentinel node dissection should be 
reserved for patients at high risk of invasive disease, such as those with high grade or large 
(>4cm) lesions[16]. 
Surgery is followed by histopathological examination to ensure clear surgical margins, 
as negative margins reduce the risk of recurrence by approximately 50%[17]. If positive 
margins (the definition of which remains controversial) are observed, the patient should 
undergo re-excision. 
Practical recommendation 
Current consensus is that BCS with selective use of whole breast radiotherapy is the 
optimal treatment for the majority of women with DCIS. Sentinel node biopsy should not be 
performed in patients having BCS. Recent studies have shown that women over 50 years of 
age treated for DCIS are more likely to be alive 10 years after diagnosis than women in the 
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general population[18]. A recent review of DCIS patients in Edinburgh treated by BCS with 
selective use of radiotherapy showed no deaths from DCIS at a median of almost 8 years.  
2.2. Adjuvant therapy 
Surgery may be followed by adjuvant radiation or endocrine therapy. Due to the limited 
knowledge of the natural history of DCIS and its risk of developing into IBC, the decision-
making process is not fully standardised and therapeutic strategies depend on local practice 
and assessment of prognostic indicators, as well as the clinician’s and patient’s attitude 
towards risks and benefits of different treatments[19–21].  
Besides positive excision margins, other risk factors for recurrence after BCS are 
tumour grade and size; patients with higher grade and/or larger DCIS appear at higher risk 
of developing IBC or recurrent DCIS after lumpectomy[22,23]. A recent UK-wide survey 
found these are the two most common factors in decision-making for adjuvant radiotherapy 
(in 51.3 and 35.5% of sites surveyed, respectively[24]). Additional independent predictors of 
progression or recurrence are younger patient age, micropapillary architecture and the 
presence of comedonecrosis[23,25–28], as well as African-American race and strong family 
history of breast cancer or BRCA1/2 mutation[27].  
2.2.1. Radiation therapy 
The need for adjuvant radiation therapy (RT) in all patients remains controversial. The 
risk of breast cancer-specific death following surgical excision of DCIS is low (about 1-4.5% 
at 15 years[29]), but the 10-year risk of local recurrence is relatively high, with studies 
estimating around 20-44% following BCS alone[30].  
The benefit from RT for patients undergoing BCS is supported by results from 4 
randomised control trials: NSABP (National Surgical Adjuvant Breast and Bowel Project) B-
17[31], DCIS-EORTC (European Organisation for Research and Treatment of Cancer) 
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10853[32], UK/ANZ (UK-Australia-New Zealand) DCIS[33,34] and SweDCIS (Swedish 
DCIS)[35–37]. These studies and subsequent meta-analyses of their results[38,39] show that 
RT following BCS for DCIS reduces overall and invasive 10-year local recurrence by 50%. 
However, some studies have attracted criticism because of incomplete determination 
of margin status and the failure to show significant improvement in overall survival with 
RT[29,40]. These studies also failed to identify a patient subgroup which derived no benefit 
from RT, adding to the growing concern of overtreatment of precursor lesions that may 
present only a low risk of recurrence or development into IBC.  
Recent efforts have failed to identify specific low-risk cohorts for whom RT can be 
safely omitted[41,42]. A retrospective study of small low-risk lesions found relatively low 
rates of 12-year ipsilateral recurrence, at 7.8%, for patients treated with BCS alone[43]. The 
more recent prospective, randomised RTOG (Radiation Therapy Oncology Group) 9804 trial 
did demonstrate that radiation decreased recurrence risk even in patients presenting small, 
low or intermediate-grade DCIS[44], although this study closed early due to limited accrual. 
Other studies of low and/or intermediate-risk DCIS patients treated with BCS alone 
have reported a substantial, cumulative risk of local recurrence[45,46]. In particular, 12-year 
follow-up results from the ECOG-ACRIN (Eastern Cooperative Oncology Group, American 
College of Radiology Imaging Network) E5194 study reported a cumulative steady increase 
in ipsilateral breast recurrence, both in situ or invasive, over time with no apparent 
plateau[45]. 
Studies currently underway aim to investigate alternative treatment strategies in 
patients with low-risk DCIS, with patients being selected based on clinical and 
histopathological characteristics, with the 10-year rate of invasive local recurrence as 
endpoint. The phase III LORD (Low Risk DCIS) trial will compare outcomes of patients 
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managed by active surveillance only, treatment with BCS alone, or BCS followed by adjuvant 
RT[47], while the UK-based LORIS (Low Risk DCIS) trial will compare two study arms of active 
surveillance or BCS[48]. 
Margin status is an important factor in determining both the risk of recurrence and the 
possible benefit from RT, since studies have confirmed that margin width is a significant 
prognostic factor of local recurrence for patients with DCIS treated with BCS alone or 
followed by RT[49–51]. Consequently, a consensus on optimal margin size has been a 
pressing need[52,53]. A recent meta-analysis of 20 studies and an accompanying review 
defined new guidelines on margins for DCIS treated by BCS with adjuvant RT[17,54]. This 
new consensus found that minimum margin of ≥2mm followed by RT minimises the risk of 
local recurrence, while wider margins do not provide any significant advantage in women 
treated with radiation. Negative close margins (<2mm) should trigger clinical review but are 
not a sufficient indication for re-excision.  
While these guidelines provide some scientific basis and do represent a consensus for a 
margin width advised to minimise recurrence, they are inconsistent with our knowledge of 
DCIS biology. For instance, the consensus for negative margins in IBC is no ink on tumour 
but in these cases the disease that is most often closest to the margin is DCIS. This raises the 
question of why DCIS associated with IBC should be considered differently from DCIS alone 
and suggests that more data are needed to refine the current consensus. 
Knowledge and understanding of IBC and DCIS dictate that the same margin guidelines 
should be used. Meta-analysis of IBC data identified 1mm as an adequate margin[55]. 
However, limited available data led to 0-1 and 1-2mm margins being combined into a single 
category of ≤2mm in the DCIS meta-analysis. Further studies in DCIS comparing 1-2 vs 1mm 
margins are required for the formulation of more specific guidelines, which should 
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represent an understanding of the biology of DCIS rather than just being simply based on 
results from analysis limited by lack of margin width data. 
Practical recommendation 
In short, BCS should aim to excise DCIS to clear margins. Following the current 
guidelines, if margins are ≥2mm then surgery is complete, while if margins are <1mm then 
re-excision is indicated. Given the limited amount of information in patients with 1-2mm 
margins and based on studies of margin width in invasive and in situ cancer together with 
the data from our recent study we do not re-excise if margins are ≥1mm.  
2.2.2. Endocrine therapy 
Studies have estimated that around 60-76% of DCIS is estrogen receptor positive 
(ER+)[56–58] (see Figure 1). Endocrine therapy (ET) has been used to treat DCIS since the 
NSABP B-24 trial first randomised patients to tamoxifen in addition to treatment with BCS 
and RT[59]. This study found a beneficial effect of adjuvant tamoxifen, with a 37% reduction 
in the relative risk of ipsilateral and contralateral cancer events[29,59,60]. Further 
retrospective analysis revealed greater benefit in ER+ patients, with an 11% absolute 
reduction in breast cancer events (vs 5.2% for patients not selected according to ER)[56,60]. 
The UK/ANZ DCIS trial showed the beneficial effect of tamoxifen in reducing both 
ipsilateral DCIS recurrence (by 30%) and contralateral primary cancer (56%), although it 
failed to show any effect on ipsilateral invasive disease[33]. Differing findings compared to 
NSABP B-24 could be related to an average younger age in the US study[33]. Additionally, 
the UK/ANZ DCIS trial has been criticised for not establishing ER status of patients accrued, 
as a lower percentage of ER+ cases may have contributed to the weaker overall effect of 
adjuvant tamoxifen[61,62]. 
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Chen et al[63] studied the efficacy of neoadjuvant ET in a small cohort of ER+ DCIS 
cases. 3-months preoperative tamoxifen (pre-menopausal patients) or letrozole (post-
menopausal), induced histologic and morphologic changes and reduced proliferation. Phase 
2 of this trial recently completed accrual and will assess letrozole alone as a neoadjuvant 
treatment. 
More recently, two phase 3 randomised control trials have compared non-steroidal 
aromatase inhibitor anastrozole and anti-oestrogen tamoxifen as adjuvant ET in women 
with hormone receptor-positive DCIS[64,65]. The IBIS-II (International Breast Cancer 
Intervention Study-II) DCIS trial compared both treatments in 2,980 postmenopausal 
women which had DCIS excision with or without subsequent RT and found no significant 
difference in prevention of ipsilateral recurrence or primary contralateral events between 
both therapies[64]. 
The NSABP B-35 trial included 3,104 patients who had DCIS excision plus RT[65]. This 
trial found both agents had similar efficacy in patients over the age of 60, while recurrence 
was reduced with anastrozole in women younger than 60, with divergence of breast cancer-
free survival curves after the first 5 years[65]. Patient-reported outcomes showed different 
side effects for each therapy, with anastrozole increasing musculoskeletal symptoms, while 
tamoxifen led to more common vasomotor problems. The under-60 cohort of patients also 
appeared to endure more severe side effects[66]. 
In short, studies have suggested a wide range of endocrine treatments are effective in 
the adjuvant setting for patients with ER+ DCIS. The efficacy of aromatase inhibitors as an 
alternative hormonal therapy to tamoxifen allows for treatment selection based on side 
effect profile for the over-60 cohort, while aromatase inhibitors are favoured for younger 
patients due to their greater efficacy if associated symptoms permit it. 
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Given the reported efficacy in reducing breast cancer events, 5 years of endocrine 
therapy is often recommended as prevention following surgery for ER+ DCIS[67]. However, 
given the lack of evidence for a survival benefit, the use of adjuvant ET varies locally 
depending on how this modest reduction of recurrence is weighed against the potential side 
effects[68,69]. Additionally, several studies have highlighted the issue of suboptimal 
adherence to ET[70–74]. Rates of non-adherence are reported to be as high as 60-
70%[70,72], with patients often discontinuing treatment due to side effects, physician 
recommendation or lack of conviction[71,72,74,75]. 
Practical recommendation 
Endocrine therapy does reduce the rates of recurrence and development of new breast 
cancer. The benefits need to be weighed against the risks of therapy. Patients should discuss 
benefits and risks with their surgeon and oncologist and reach a joint decision of what is 
best for that individual. 
2.2.3. HER2-targeted therapy 
Studies in DCIS have reported a variable incidence of human epidermal growth factor 
receptor 2 (HER2) overexpression between populations. However, a recent review of 8 
clinical trials and 36 observational studies estimated that about 40% of DCIS lesions are 
HER2+[57], suggesting a subpopulation of DCIS could benefit from HER2-targeted therapy 
(see Figure 1). A meta-analysis reported that HER2+ DCIS is associated with an increased risk 
of recurrence[28]. Although the clinical utility of HER2 status in the management of DCIS is 
still unclear, it has become the focus of recent research. 
An open-label phase II trial assessing the effect of 4-weeks pre-surgical treatment with 
the tyrosine kinase inhibitor lapatinib in 20 patients reported a significant inhibition of HER2 
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pathway signalling and reduced tumour size[76]. An ongoing randomised phase I/II clinical 
trial (NCT00555152) will study the efficacy and side effects of lapatinib in HER2+ DCIS. 
Another open-label phase II study assessed the effect of 2-4 weeks pre-surgical 
treatment with the HER2-targeting monoclonal antibody trastuzumab in 69 patients with 
DCIS[77]. Although results suggested an increase in immunoresponse, they failed to show 
significant changes in histology, proliferation or apoptosis. 
The ongoing NSABP B-43 study is the first prospective randomised phase III clinical trial 
to assess the effect of trastuzumab on local recurrence. A total of 1,428 patients which 
underwent excision of HER2+ DCIS were randomly assigned to receive radiotherapy alone or 
with trastuzumab, with no significant differences in toxicity observed between both 
arms[78].  
Practical recommendation 
As this trial is still underway and further studies are needed to assess the possible 
application of this treatment, currently HER2-directed therapy has no established role in 
treatment of HER2+ DCIS. 
3. CHALLENGES IN THE MANAGEMENT OF DCIS: THE NEED FOR PREDICTIVE TOOLS 
The last two decades have seen the improvement in our understanding of DCIS, the 
establishing of treatment consensus for certain categories of DCIS and the search for 
effective therapeutic approaches. However, due to heterogeneity and complex natural 
history of DCIS, we are still unable to determine which non-invasive lesions will become 
invasive if untreated or to predict the risk of recurrence as either DCIS or IBC following 
treatment[19]. These issues contribute to a lack of consensus on management[19], 
complicate communication with patients[79,80] and are a hurdle to optimising treatment 
for individual patients[81]. 
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The ultimate goal of therapy for DCIS is to prevent development of IBC. The main 
challenge resides in tailoring treatment to individual risk, to avoid both over-treatment of 
lesions that may never develop into IBC and under-treatment of DCIS with high risk of post-
excision recurrence as DCIS or IBC[81]. A review of autopsy studies revealed that 8.9% of 
women who died of causes other than breast cancer had undetected DCIS in their 
breasts[82]. Studies have found that screening with mammography in addition to clinical 
examination leads to a 4-fold increase in DCIS detection but fails to reduce mortality[83,84]. 
In order to improve clinical management of DCIS, accurate prognostic markers are 
needed to define low-risk DCIS cohorts for whom adjuvant therapy could be safely omitted, 
or high-risk cohorts which require additional systemic and/or targeted treatments to 
prevent recurrence. Histopathological and host factors such as DCIS grade are currently 
used to guide clinicians in the decision-making process, but low grade does not always 
necessarily mean low risk and better predictors are needed. 
3.1. Predictive tools based on clinical and histopathological markers 
- Van Nuys prognostic index 
In the 1990s, Silverstein and collaborators in the University of Southern California (USC) 
developed the Van Nuys prognostic index (VNPI) to predict the risk of local recurrence 
following excision of DCIS. This clinical algorithm incorporated tumour size, margin width 
and pathologic classification (based on nuclear grade and presence/absence of 
comedonecrosis) as key risk factors for recurrence[49,85,86]. Patient age was subsequently 
identified as an independent predictor of local recurrence[87–89] and incorporated as a 
fourth factor into an amended VNPI algorithm[86] (see Table 1). 
Each factor is assigned a score of 1 (better prognosis) to 3 (worse prognosis), providing 
an overall VNPI score which classifies DCIS lesions into different risk of recurrence groups 
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with associated treatment guideline: excision only (low risk: 4-6), excision plus RT (moderate 
risk: 7-9) or mastectomy (high risk: 10-12). These guidelines, based on which cohorts gained 
benefit from the addition of adjuvant RT, aimed to achieve less than a 20% local recurrence 
rate after 12 years for each group[86] and have been subsequently updated, considering 
margin width to refine treatment selection for cases in the intermediate risk group[90].  
However, this index was based on a retrospective multivariate analysis of pooled data 
from a single institution and lacks robust independent prognostic validation; some studies 
supporting its efficacy[25,91], while others found no benefit from its application[92]. A 
study assessing validity of the VNPI in a UK population showed that it lacked discriminatory 
power to adequately stratify patients[50]. This study also criticised the VNPI pathologic 
classification and argued that the simpler DCIS nuclear grading system used across the UK 
and Europe (low, intermediate or high, without considering the presence/absence of 
comedonecrosis) allows greater reproducibility[50]. Additionally, although the USC group 
initially reported that patients with wide negative excision margins (>10mm) derived little 
added benefit from radiotherapy[93], more recent data suggests even this group gain 
benefit from radiation[94]. 
In short, the VNPI has not been shown unequivocally to be of clinical utility and this has 
hindered its acceptance into clinical practice. The use of this tool has also lacked support in 
the UK[50], with a recent survey revealing that only 15.8% of breast units across the country 
use it routinely and even in these sites there is a lack of consistency in the scores applied in 
the decision-making process[24]. 
- Nomograms 
Recent years have seen the development of nomograms which integrate different 
clinical and histopathological factors to predict recurrence[95–99]. Van Zee and 
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collaborators used data from 1,681 women with DCIS to design a Memorial Sloan-Kettering 
Cancer Center (MSKCC) model, based on 10 markers including features such as age and 
tumour properties, but also the administration of adjuvant radiation or endocrine 
therapy[95] (see Table 1).  
This nomogram estimates the 5 and 10-year risk of absolute recurrence and has been 
validated on external populations[100–102]. However, this nomogram has been criticised 
for not integrating molecular predictors such as hormone receptors or markers of 
proliferation and reviewers have suggested that it is likely to underestimate the 
heterogeneity of DCIS lesions[103]. 
Indeed, prognostic tools relying exclusively on clinico-histopathological markers and 
treatment choices for risk prediction are limited in their scope. Despite integrating markers 
which significantly affect recurrence, these tools fail to identify and stratify cohorts of DCIS 
patients with inherently different risks of recurrence due to their molecular profile. While it 
is well established that smaller lesions or adjuvant treatment will positively affect the 
chances of recurrent disease, the real clinical need is for tools that identify which lesions 
actually require such therapies in order to prevent over- or under-treatment.  
3.2. Predictive tools based on molecular markers  
- Oncotype DX DCIS Score 
In 2013, Solin and collaborators used a rigorous prospective-retrospective design based 
on archived data from 5 different studies to develop a new prognostic tool based on the 21-
gene Oncotype DX assay[104]. This led to a specific DCIS Score (DS) based on the expression 
level of 7 genes, including markers of proliferation and the progesterone receptor (PR), 
normalised to 5 reference genes (see Table 1). This continuous score (0-100) stratified 
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patients into groups with low (<39), intermediate (39-54) and high (≥55) risk of recurrence 
at 10 years[104].  
Validation on a series of 327 patients with low-risk DCIS treated with BCS only, from the 
ECOG-AGRIN E5194 trial[105], found that DS could quantify the risk of both overall and 
invasive local recurrence[104]. Further validation in a similar Ontario-based population of 
718 patients supported the value of DS as an independent predictor of risk of local 
recurrence[106]. Two recent US-based multi-institutional clinical utility studies have shown 
that application of DS has led to significant changes in treatment recommendations, 
suggesting that clinicians are considering the information provided by the test in their 
decision-making process[107,108]. 
However, several factors have prevented the adoption of this new prognostic tool on a 
global scale. Firstly, reviewers have criticised the fact that DS has only been validated on 
low-risk DCIS patients who meet the strict criteria defined by the original ECOG-ACRIN 
E5194 trial[109,110]. 
Another obstacle is the cost of this assay, which at $4175 per test is prohibitive for its 
application in most health services outside the US. Indeed, a recent study found no 
treatment strategies incorporating this test are cost-effective[111]. A recent UK-based 
survey studying trends in DCIS management found only 1 site out of the 76 surveyed used 
this test routinely[24]. Additionally, like all other Oncotype assays, the DS test needs to be 
shipped to a central laboratory for processing and analysis, adding logistical constraints in 
countries outside the US.  
Most importantly, the actual prognostic value of the different DCIS risk groups 
identified by this test has been questioned. The 10-year rates of local recurrence for low, 
intermediate and high-risk groups were validated in the two aforementioned studies as 
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10.6-12.7, 26.7-33.0 and 25.9-27.8%, respectively[104,112]. However, the low-risk group is 
still associated with an 11-13% risk of recurrence, which some clinicians consider high 
enough to prescribe adjuvant treatment[110]. Furthermore, this scoring system fails to 
adequately stratify between intermediate (27-33%) and high-risk (26-28%) patients, 
demonstrating the limitations of a continuous rather than a discreet prognostic score and 
hindering its practical application. Furthermore, this test relies exclusively on markers 
derived from the established DCIS knowledge base (proliferation and hormone status), 
failing to take advantage of novel marker discovery in its design, which could improve its 
predictive power. 
In short, how the tool has been developed, the limited validation in low-risk groups 
only, the continuous nature of the scoring system and the fact that DS considers only a 
multigene signature without factoring in other clinical and pathological prognosticators of 
proven significance suggest that, even if logistical and monetary factors were not an issue, 
the Oncotype DX DCIS Score is unlikely to function as a reliable, global test for the majority 
of patients worldwide with DCIS. 
- Hormone receptor status and molecular phenotypes as risk predictors 
A recent study by Bundred and collaborators assessed the expression level of hormone 
receptors (ER, PR and HER2) in 314 women with DCIS[113]. Immunohistochemistry 
surrogates allowed for stratification of DCIS into molecular phenotypes: Luminal A 
(ER/PR+,HER2-), Luminal B (ER/PR+,HER2+), HER2 type (ER-,PR-,HER2+) or triple negative 
(ER-,PR-,HER2-).  
Comparison of recurrence rates with 10-year follow-up found that molecular 
phenotype was an independent predictor of both overall and invasive recurrence. Luminal A 
DCIS demonstrated the lowest rate of overall and invasive 10-year recurrence (7.6 and 1.3%, 
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respectively)[113], suggesting these lesions could be treated with BCS only. In contrast, 
HER2 type DCIS had the highest rate of overall and invasive 10-year recurrence (47.7 and 
29.5%, respectively). This phenotype was the independent predictor with the highest risk 
for both overall (HR 6.46, P < 0.001) and invasive recurrence (HR 11.4, P = 0.027) when 
compared with Luminal A DCIS[113], encouraging the further study of HER2-targeted 
therapies for the management of DCIS.  
While these results are supported by previous studies which linked both ER/PR- 
status[114] and HER2+ status[28,114,115] to increased risk of recurrence, a recent study in 
a cohort of 230 DCIS cases found no significant correlation between these markers and 
recurrence[116]. This divergence highlights the need for further work before the potential 
clinical utility of hormone and HER2 receptor status can be confirmed. 
- Other biological markers 
The Bundred study also identified high expression of the marker of proliferation Ki67 as 
an independent predictor for invasive recurrence (>14% HR 1.05, P = 0.021, per %)[113]. 
Other studies have also linked high Ki67 to an increased risk of in situ recurrence. However, 
the value of Ki67 as a potential predictive factor is hindered by variation and lack of 
consensus in its quantification across sites[117,118]. 
Other markers identified as independent predictors of recurrence in DCIS cases are 
COX-2[119–122] and cell cycle-related proteins p51[123] and p53[124,125]. However, 
further validation with sufficient follow-up and standardised detection methods are 
necessary before these markers can be of clinical use[110]. 
3.3. Predictive tools integrating clinical, histopathological and molecular factors 
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Other studies have integrated molecular biomarkers with clinical and histopathological 
parameters to develop risk-prediction tools with greater efficacy, accuracy, reproducibility 
and clinical utility than methods relying on one type of predictive marker only[126]. 
For instance, Altintas et al[127] refined the VNPI by replacing the nuclear grade factor 
for a 4-gene signature (genomic grade index, GGI, see Table 1), improving the statistical 
association between high scores and risk of recurrence (HR 18.14 for updated VNPI-GGI 
method, vs HR 7.72 for conventional VNPI). This translated into a more accurate 
identification of high-risk DCIS with early recurrence within 5 years[127], although further 
validation in a larger trial is necessary to ascertain the clinical utility of this improved index. 
Other groups have investigated the correlation of the gene signature-based Oncotype 
DX DCSI Score with clinical and histopathological markers[128,129]. Results have found only 
moderate correlation with outcome, suggesting that prognostic strategies based on 
different types of variables are not necessarily additive and, thus, cannot be simply 
combined. This supports the notion that the relationship between these different factors 
may be complex and their integration is challenging, though it may hold the potential to 
provide more accurate and reproducible prognostic tools than either clinical, 
histopathological or biological factors alone. 
4.  A UK-WIDE PROSPECTIVE AUDIT OF DCIS: THE SLOANE PROJECT 
The Sloane Project is an ongoing multi-disciplinary, UK-wide prospective audit of 
screen-detected DCIS, LCIS and atypical hyperplasia of the breast. By correlating information 
on the clinical management and outcome of each case (with follow-up data on local 
recurrence, contralateral disease, metastases and death[130]), this audit aims to identify 
prognostic indicators and establish the role of margins and adjuvant therapy to improve 
treatment strategies for DCIS. The National Institute for Health and Care Excellence (NICE) 
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endorsed this audit[131] and 50% of all screen-detected DCIS diagnosed in the UK have 
been entered[132], with a total of 10,582 cases included as of October 2014[133].  
Preliminary results revealed marked variation in the use of adjuvant RT following 
BCS[134], although patients were more likely to receive RT if they presented large (≥15mm), 
intermediate or high-grade lesions or if comedonecrosis was observed[134]. Results suggest 
that some clinicians apply the VNPI as a tool, despite margin width alone not being an 
influencing factor in the decision-making process[134].  
More recent results suggest that factors such as close margins, large lesion size and 
microinvasion may be sufficient to consider RT following mastectomy for DCIS to reduce the 
risk of ipsilateral recurrence[135]. However, the risk of recurrence is small even in patients 
who did not receive RT, so the benefit of radiation may be limited. 
Results have shown that preoperative imaging underestimates lesion size in 30% of 
cases[136] and, together with practice variation, this contributes to adverse surgical 
outcome as failed BCS or mastectomy for small lesions in approximately 15% of cases in an 
8,313 patient cohort[132]. Better pre-surgical assessment of the extent and nature of DCIS 
by standardisation and multidisciplinary integration of radiological and histopathological 
data could improve the surgical management of some patients[132].  
Improved sampling, ultrasonic assessment and risk stratification are also needed to 
reduce variation in and unnecessary surgery in patients currently undergoing axillary 
assessment[137]. Survey results also showed a lack of nationwide consistency in the 
methods and thresholds used in ER scoring[138], as well as in duration and frequency of 
follow-up after treatment[139]. 
Although the first phase of the Sloane Project has now closed, follow-up of patients 
enrolled continues to collect information on recurrences and survival[140]. Other ongoing 
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work includes a registrational study of untreated DCIS lesions (the ‘Forget Me Not’ project). 
The multidisciplinary team behind the Sloane Project also put together the LORIS trial[48] 
and aims for collaboration between both studies in the future. 
The second phase of the project, still in the early stages, focuses on the research arm. 
This aims to identify biomarkers from clinical DCIS samples at diagnosis and recurrence, in 
an effort to find molecular classifiers predicting recurrence risk, prognosis and benefit from 
treatment[133,141]. Given that treatment itself has a huge influence on recurrence rates, 
the challenge for this project will be to identify significant biological markers against a 
background of hugely variable clinical management between centres. The heterogeneity in 
margin widths was a hurdle the consensus conference failed to overcome so it is anticipated 
that the Sloane Project will face similar issues.  
5. CONCLUSION 
In the last few decades, the introduction of breast screening programmes has led to a 
huge increase in DCIS diagnoses. Evidence suggests DCIS encompasses lesions that are 
heterogeneous in their biology and, consequently, present varying risks of recurrence 
following excision, or progression if untreated.  
To date, clinicians lack tools to predict which lesions are most likely to progress to 
invasive disease or to recur following treatment. The current consensus is for the majority 
of patients to receive wide local excision with clear margins. Mastectomy can be performed 
depending on clinical and histological factors.  
The administration of adjuvant therapy varies greatly across sites due to a poorly-
standardised decision-making process. While adjuvant radiotherapy can reduce 10-year 
local recurrence by 50%, current efforts focus on identifying low-risk patients for whom RT 
can be safely omitted and the definition of a margin width consensus. Adjuvant tamoxifen 
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and aromatase inhibitors can reduce risk of subsequent cancer events in patients treated for 
ER+ DCIS, but the use of adjuvant ET is limited by variation in uptake and poor adherence. 
The primary objective of management of DCIS is to provide treatment to patients which 
is relative to their risks of progression and recurrence. Tailoring of treatment to each 
patient’s individual risk, would help to improve clinical outcomes while at the same time 
reducing the amount of therapy required, avoiding both under- and over-treatment. 
Molecular, clinical and histopathological factors identified as independent 
prognosticators have been used to develop predictive tools, but shortcomings including 
limited validation and questionable discriminatory powers or prognostic values have 
prevented their widespread adoption (see Table 1). In addition, the VNPI or the MSKCC 
nomogram fail to incorporate molecular predictors, while the Oncotype DX DCIS Score 
comes with logistic and cost limitations. Predictive molecular phenotypes and other 
biological markers will require further research and the definition of appropriate guidelines 
before they can be of use. 
The clinical database created by the UK-based Sloane Project has also shed light on 
trends in the management of DCIS and highlighted nationwide inconsistencies, calling for 
the establishment of better defined standards of practice. Its research phase will face the 
challenge of identifying significant markers against the background of treatment variation. 
There is a pressing clinical need for better and more accurate prognostic tools capable 
of stratifying DCIS lesions according to their different biology and associated behaviour. 
Future efforts need to focus on the integration of clinical and histopathological factors 
together with identification of new molecular biomarkers (possibly at gene expression and 
protein levels). The development of such tools could provide an optimal classification of 
patients into risk groups of clinical utility, to help provide accurate guidance on treatment 
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and assist in the development of standardised practices for the management of the many 
patients now diagnosed with DCIS. 
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Prognostic tool Factors Outcome Limitations 
Van Nuys 
prognostic index 
(VNPI) 
- Lesion size (≤15mm, 16-40mm or >40mm) 
- Margin width (≥10mm, 1-9mm, <1mm) 
- Pathologic classification (grade ± comedonecrosis) 
- Patient age (>60, 40-60, <40) 
Total score (4-12) stratifies into 3 groups 
with different risks of recurrence and 
treatment guidelines to achieve <20% 
local recurrence at 12 years 
- Fails to incorporate molecular predictors 
- Lacks robust independent validation 
- May lack discriminatory power 
- Pathologic classification may have poor reproducibility 
Memorial Sloan-
Kettering Cancer 
Center (MSKCC) 
nomogram 
- Age at diagnosis (90-25) 
- Family history (no/yes) 
- Initial presentation (radiologic/clinical) 
- Radiation (yes/no) 
- Adjuvant ET (yes/no) 
- Nuclear grade (low or intermediate/high) 
- Necrosis (absent/present) 
- Margins (negative or positive/close) 
- Number of excisions (≤2 or ≥3) 
- Year of surgery (≥1999 or ≤1998) 
Total score (0-500) to predict 5 and 10-
year probability of absolute ipsilateral 
recurrence 
- Fails to incorporate molecular predictors 
- May underestimate heterogeneity of DCIS lesions 
Oncotype DX        
DCIS Score (DS) 
- RT-PCR expression levels of 7 cancer-related genes: 5 
markers of proliferation (Ki67, STK65, Survivin, CCNB1, 
MYBL2), PR and GSTM1; normalised to 5 reference genes 
(ACTB, GAPDH, RPLPO, GUS, TFRC) 
Continuous score (0-100) stratifies into 3 
groups with different risks of recurrence 
at 10 years 
- Lacks wider validation in independent cohorts 
- High cost 
- Requires shipping to central laboratory 
- Prognostic value has been questioned 
- Poor stratification of intermediate and high-risk lesions 
- Fails to incorporate novel molecular markers 
Molecular 
phenotypes 
- IHC surrogates for ER, PR and HER2 to classify into 4 
molecular phenotypes (Luminal A, Luminal B, HER2 or 
triple negative) 
Phenotypes are independent predictors 
of overall and invasive recurrence at 10 
years 
- Uneven results in validation 
Other biological 
markers 
- IHC measurement of COX-2, p51 or p53 
Expression levels of biomarkers are 
independent predictors of recurrence 
- Variation in methodology 
- Further validation with sufficient follow-up needed 
Van Nuys 
prognostic index 
adjusted with 
genomic grade 
index (VNPI-GGI) 
- Lesion size (≤15mm, 16-40mm or >40mm) 
- Margin width (≥10mm, 1-9mm, <1mm) 
- Patient age (>60, 40-60, <40) 
- GGI: RT-PCR expression levels of 4 genes linked to 
proliferation (MYBL2, KPNA2, CDC2, CDC20), normalised 
to 4 reference genes (GUS, TBO, RPLP0, TFRC) 
Total VNPI-GGI score (4-12) classifies into 
3 risk groups with more accurate 
identification of high-risk lesions with 
early recurrence within 5 years than 
VNPI score 
- Need for further validation 
- Fails to address other limitations of the original VNPI 
Table 1 Summary of the main prognostic tools for prediction of risk of recurrence following surgical excision of DCIS lesions, their methodology and main 
shortcomings preventing their widespread adoption to date. 
Table1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Histologic and immunochemistry features of ductal carcinoma in situ of the breast. This microscopy images depict some of the 
features typically observed upon pathologic assessment of precursor lesions. (a) Low grade DCIS: this duct is filled with small very 
homogeneous ductal epithelial cells typical of low grade precursor lesions. (b) Intermediate grade DCIS: a population of intermediate sized but 
monotonous cells fill this duct. (c) High grade DCIS: highly pleomorphic and b nucleolated cells fill this duct profile, with a small amount of 
central comedonecrosis. (d) Low grade ER+ DCIS: this duct presents low grade DCIS which is uniformly positive for ER. (e) High grade ER+ DCIS: 
100µm 
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Figure1
  
only some of the cells filling this duct profile showing high grade DCIS are staining positive for ER, suggesting that a good response to endocrine 
therapy is unlikely. (f) High grade HER2+ DCIS: this duct shows high grade disease, which is more commonly HER2+ than invasive carcinoma, 
with strong positive HER2 staining. This patient also had HER2+ invasive disease. 
 
  
 Some DCIS lesions would never become clinically apparent if left untreated. 
 Clinical management is limited by a lack consensus and inadequate risk prediction. 
 Treatment needs to be tailored to the actual risk of recurrence or progression. 
 No prognostic tools have been globally validated or have routine clinical utility. 
 Integrating several types of predictive factors holds greater prognostic potential. 
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